Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.

Philipp EiseleKristina SzaboAnne EbertMichael PlattenAchim Gass

Published in: Journal of neuroimaging : official journal of the American Society of Neuroimaging (2018)

Our results contribute to the increasing knowledge of PBVCs in natalizumab-treated MS patients. Our data suggests that after a significant PBVC decrease in the first year, brain atrophy rates show a slowdown during long-term follow-up.

Keyphrases

multiple sclerosis
newly diagnosed
white matter
end stage renal disease
resting state
ejection fraction
healthcare
chronic kidney disease
mass spectrometry
peritoneal dialysis
prognostic factors
functional connectivity
ms ms
machine learning
patient reported outcomes
deep learning